Pharmacokinetics, exposure, efficacy and safety of obinutuzumab in rituximab‐refractory follicular lymphoma patients in the GADOLIN phase III study
2019 ◽
Vol 85
(9)
◽
pp. 1935-1945
◽
Keyword(s):
Keyword(s):
Keyword(s):
Keyword(s):
2018 ◽
Vol 48
(8)
◽
pp. 777-780
◽
Keyword(s):
Keyword(s):
Keyword(s):
2010 ◽
Vol 88
(1)
◽
pp. 12-19
◽
Keyword(s):